Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. REBLOZYL (luspatercept)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

REBLOZYL (luspatercept)

Medicine - Posted on Jan 25 2024
Active substance (DCI)
  • luspatercept
history (3)
  • 1/22/24

    REBLOZYL (luspatercept) - Anémie associée à une bêta-thalassémie

    Le laboratoire a informé la HAS de sa demande de non remboursement dans l’indication « Reblozyl est indiqué chez les adultes...
    icône flèche
  • 6/16/21

    REBLOZYL 25 - (ß-thalassémie) (luspatercept)

    Key points Unfavourable opinion for reimbursement in the treatment of adult patients with transfusion-dependent anaemia asso...
    icône flèche
  • 6/2/21

    REBLOZYL (luspatercept) (syndrome myélodysplasique - SMD)

    Key points Favourable opinion for reimbursement in the treatment of adult patients with transfusion-dependent anaemia due to...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • B03XA06
Manufacturer
BRISTOL-MYERS SQUIBB
Presentation

REBLOZYL 25 mg, poudre pour solution injectable
1 flacon en verre de 3 ml (CIP : 34009 302 121 4 1)

REBLOZYL 75 mg, poudre pour solution injectable
1 flacon en verre de 3 ml (CIP : 34009 302 121 7 2)

All our publications
    Anemia and hemoglobinopathies Bone marrow diseases Congenital, genetic and rare diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mF1v2jAUhu/5FVHuSYCWNp0C1cbaDWnVGC3atJvKJIdi5trpsc1Hf/0cQjc6Oepq6svE9ntOfF4/Pkp6vr5nwRJQUsF7YTtqhQHwTOSU3/XCyc1lMwnP+410QZZkb9pp1IranTDIGJGyF5aj0RQIl9GPqy8fwawHDPuNIBXTBWTq2TytKIs+Ezm/IkU5J0iXgubBPai5yHthodX2bZBKhSaL/krgL1mQDNJ492Z/dHF7vP8+jUux/1DVEvAL4XdWUeBOmplGBK4GRMGdwE1NvkdO2lSOQQqNGYyImo9QLGkOuTXEjDAJTkFmq/wacMlAlUGs4vEiu5dO4mRB1mN4GNqTfm9GB2qtmq1m+/T4rHWSJMlRt9V1CoV7W2WvgvmIuLg96iTtTpLEwGOEKROPG9Zk2phNgVldKMdKjQQqwjzViMrBc5t5ioPw8KIXcioLRjbRQhauW0WQmGFAAwN/H1J+wQ0aPDGzZ//oc81Y/MqsJzt4eMq4ZNNAaK5qGHI5dt2IgeAK1vUVdcOeWu+8SEG+neyj4Hbkj/SU0cwVcAZBGqSajIf1fPOHhg9EwgT9seE75blYybdnzn6NPWVfbLFpFS0wb992zpKTdrfrfKR+GkPV3D4XGkUBsaERlYdAZshn4lC8GI/apZ4c6smc245IZIRBTU/UdOSOceVTC+fN9/7OVDVgFf10ceNqlm8acHO9fbRK07z3p8xuUPZBemPN2sRfb/TqvHvpljXaOTJXqpDv4ni1WkVzIpuSmF2KZuiZ+nvXrr/O3cvdXvU6FTk9pT6trsTX1cv13L10+x/a0e7W7zpnawyFGg6oRYVobyAdXrw9m/+2s97SHj1jib8w29aTKCq4ryZIT+0d0EG3gakrv0QDiK+zGa35k1LryzSu/uL0G2lc/sHpN34D/lz8VA==
ZfhCCgNJFV4TPUsZ